[go: up one dir, main page]

CA2231434A1 - Methode de prevention de l'alopecie androgenetique par des inhibiteurs de la 5-.alpha. reductase - Google Patents

Methode de prevention de l'alopecie androgenetique par des inhibiteurs de la 5-.alpha. reductase Download PDF

Info

Publication number
CA2231434A1
CA2231434A1 CA002231434A CA2231434A CA2231434A1 CA 2231434 A1 CA2231434 A1 CA 2231434A1 CA 002231434 A CA002231434 A CA 002231434A CA 2231434 A CA2231434 A CA 2231434A CA 2231434 A1 CA2231434 A1 CA 2231434A1
Authority
CA
Canada
Prior art keywords
alpha
day
beta
androst
aza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002231434A
Other languages
English (en)
Inventor
Glenn J. Gormley
Keith D. Kaufman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602834.5A external-priority patent/GB9602834D0/en
Application filed by Individual filed Critical Individual
Publication of CA2231434A1 publication Critical patent/CA2231434A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention couvre un procédé destiné à prévenir l'alopécie androgénétique, à encourager la pousse des cheveux et consistant à administrer aux patients, notamment aux individus prédisposés à l'alopécie androgénétique, y compris aux hommes présentant des niveaux d'androgènes normaux mais qui ont une prédisposition génétique à développer une alopécie androgénétique, une dose, propre à maintenir la quantité de cheveux, d'un inhibiteur de la 5.alpha.-réductase 2, du type finastéride.
CA002231434A 1995-09-27 1996-09-23 Methode de prevention de l'alopecie androgenetique par des inhibiteurs de la 5-.alpha. reductase Abandoned CA2231434A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US442195P 1995-09-27 1995-09-27
US60/004,421 1995-09-27
GB9602834.5 1996-02-13
GBGB9602834.5A GB9602834D0 (en) 1996-02-13 1996-02-13 Method of preventing androgenetic alopecia with 5-alpha reductase inhibitors

Publications (1)

Publication Number Publication Date
CA2231434A1 true CA2231434A1 (fr) 1997-04-03

Family

ID=26308658

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002231434A Abandoned CA2231434A1 (fr) 1995-09-27 1996-09-23 Methode de prevention de l'alopecie androgenetique par des inhibiteurs de la 5-.alpha. reductase

Country Status (5)

Country Link
EP (1) EP0859617A1 (fr)
JP (1) JPH11513380A (fr)
AU (1) AU7078296A (fr)
CA (1) CA2231434A1 (fr)
WO (1) WO1997011702A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001844A (en) 1995-09-15 1999-12-14 Merck & Co., Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
WO1999006050A1 (fr) 1997-07-29 1999-02-11 Sankyo Company, Limited Agent reparateur contre la calvitie et autres maladies
GB9717444D0 (en) * 1997-08-19 1997-10-22 Glaxo Group Ltd Pharmaceutical composition
IL124764A0 (en) * 1998-06-04 1999-01-26 Univ Ben Gurion Topical composition for treatment of baldness
EP1154783A4 (fr) * 1999-07-06 2005-01-19 Raziel Lurie Medicaments comprenant de la relaxine et leur utilisation
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
GB201102913D0 (en) 2011-02-18 2011-04-06 Univ Birmingham Novel therapeutic

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
EP0285382B1 (fr) * 1987-04-03 1994-04-13 Merck & Co. Inc. Traitement d'alopécia androgénique avec 17-bêta-n-monosubstitué-carbamoyl-4-aza-5-alpha-androst-1-en-3-ones
ZA883034B (en) * 1987-04-29 1989-03-29 Smithkline Beckman Corp Steroid 5-alpha-reductase inhibitors
GB9002922D0 (en) * 1990-02-09 1990-04-04 Erba Carlo Spa 17 beta-substituted-4-aza-5 alpha-androstan-3-one derivatives and process for their preparation
US5516768A (en) * 1990-03-16 1996-05-14 Smithkline Beecham Corporation Uncompetitive inhibition of steroid and 5α-reductose
GB9115676D0 (en) * 1991-07-19 1991-09-04 Erba Carlo Spa Process for the preparation of 17 beta substituted-4-aza-5 alpha-androstan-3-one derivatives
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids

Also Published As

Publication number Publication date
EP0859617A1 (fr) 1998-08-26
WO1997011702A1 (fr) 1997-04-03
AU7078296A (en) 1997-04-17
JPH11513380A (ja) 1999-11-16

Similar Documents

Publication Publication Date Title
US5547957A (en) Method of treating androgenic alopecia with 5-α reductase inhibitors
CA2173457C (fr) Utilisation des inhibiteurs de la 5-alpha reductase et compositions pour le traitement de l'alopecie androgenique
HK1000933B (en) Method of treating androgenic alopecia with 5-alpha reductase inhibitors
CA2231434A1 (fr) Methode de prevention de l'alopecie androgenetique par des inhibiteurs de la 5-.alpha. reductase
US5763361A (en) 17-alkyl-7-substituted-4-aza steroid derivatives as 5-α-reductase inhibitors
JPH11513684A (ja) １６−置換−６−アザ−ステロイド５α−レダクターゼ阻害剤
AU722260B2 (en) 17-alkyl-7-substituted-4-aza steroid derivatives
AU688395C (en) Method of treating androgenic alopecia with 5-alpha reductase inhibitors
RU2173152C2 (ru) Способ лечения андрогенной алопеции ингибиторами 5-альфа-редуктазы
CA2231041A1 (fr) 4-azasteroides utilises pour le traitement d'etats hyperandrogeniques
HK1009247A (en) Method of treating androgenic alopecia with 5-alpha reductase inhibitors

Legal Events

Date Code Title Description
FZDE Dead